77 results
8-K
EX-10.1
CRVO
CervoMed Inc
20 May 24
CervoMed to Appoint William Elder as Chief Financial Officer
4:07pm
or not consecutive) during any period of twelve (12) consecutive months, as a result of injury, illness or any other physical or mental impairment.
1.11. “Good
8-K
EX-10.2
CRVO
CervoMed Inc
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
of twelve (12) consecutive months, as a result of injury, illness or any other physical or mental impairment.
1.11. “Good Reason” means any
8-K
EX-10.3
CRVO
CervoMed Inc
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
(whether or not consecutive) during any period of twelve (12) consecutive months, as a result of injury, illness or any other physical or mental impairment
8-K
EX-10.1
fcn5bo2z53go6k9f
2 Feb 24
Entry into a Material Definitive Agreement
4:17pm
8-K
EX-10.1
ar0ks7muh 536
17 Nov 23
Entry into a Material Definitive Agreement
5:03pm
8-K/A
EX-99.2
ndjwv ubhg6b
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.3
vvcarn
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
424B3
z8d3k
13 Jul 23
Prospectus supplement
4:32pm
S-4/A
aavcjez y8e
22 Jun 23
Registration of securities issued in business combination transactions (amended)
9:46pm
S-4
irefm4i5txbkgkd89h0i
10 May 23
Registration of securities issued in business combination transactions
9:56pm
425
EX-10.2
v73ay
30 Mar 23
Business combination disclosure
8:51am
8-K
EX-10.2
wzl kavr4vkw4f9ce5n2
30 Mar 23
Form of Parent Stockholder Support Agreement
8:50am
8-K
EX-10.1
j986hpv8vuas
16 Dec 22
Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities
5:10pm
424B5
p5x5gg
22 Jul 22
Prospectus supplement for primary offering
4:15pm
8-K
EX-10.1
shwl0vj5gphttvm ixa
28 Jun 22
Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial
4:13pm